Quick Answer
Silexion Therapeutics Corp reported Stockholders Equity of $2.60 million for fiscal year 2025.
Silexion Therapeutics Corp Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $2.60M | +165.3% |
| 2024 | -$3.99M | +74.2% |
| 2023 | -$15.48M | -304.5% |
| 2022 | $7.57M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.98M | +252.4% | +5714.2% |
| June 30, 2025 | $120.0K | +100.7% | -95.4% |
| March 31, 2025 | $2.59M | +60.6% | +164.8% |
| December 31, 2024 | -$3.99M | +74.2% | +12.9% |
| September 30, 2024 | -$4.58M | +1.5% | +74.9% |
| June 30, 2024 | -$18.26M | -436.6% | -1234.0% |
| March 31, 2024 | $1.61M | -76.5% | +110.4% |
| December 31, 2023 | -$15.48M | -304.5% | -233.0% |
- Silexion Therapeutics Corp showed an increase of +165.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Silexion Therapeutics Corp’s stockholders equity has declined by 65.6% (from $7.57 million to $2.60 million).
- The most recent figure is from Silexion Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: